Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
77.91
-1.14 (-1.44%)
May 29, 2026, 4:00 PM EDT - Market closed
Arrowhead Pharmaceuticals Employees
Arrowhead Pharmaceuticals had 711 employees as of September 30, 2025. The number of employees increased by 102 or 16.75% compared to the previous year.
Employees
711
Change (1Y)
102
Growth (1Y)
16.75%
Revenue / Employee
$874,837
Profits / Employee
-$423,221
Market Cap
10.97B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 711 | 102 | 16.75% |
| Sep 30, 2024 | 609 | 84 | 16.00% |
| Sep 30, 2023 | 525 | 128 | 32.24% |
| Sep 30, 2022 | 397 | 68 | 20.67% |
| Sep 30, 2021 | 329 | 97 | 41.81% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Ionis Pharmaceuticals | 1,402 |
| Axsome Therapeutics | 1,220 |
| Exelixis | 1,077 |
| Madrigal Pharmaceuticals | 915 |
| BridgeBio Pharma | 839 |
| Cytokinetics | 673 |
| Krystal Biotech | 295 |
ARWR News
- 4 days ago - Arrowhead presents interim results from Phase 1/2a trial of ARO-INHBE - TheFly
- 4 days ago - Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026 - Business Wire
- 5 days ago - Arrowhead presents clinical cardiometabolic data at EAS Congress - TheFly
- 5 days ago - Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress - Business Wire
- 11 days ago - Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum - MarketBeat
- 11 days ago - Arrowhead Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026 - Transcripts
- 17 days ago - Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts Near - MarketBeat
- 18 days ago - Arrowhead Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts